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Background: Individuals severely affected by autism spectrum disorder (ASD), including those with intellectual
disability, expressive language impairment, and/or self-injurious behavior (SIB), are underrepresented in the ASD
literature and extant collections of phenotypic and biological data. An understanding of ASD’s etiology and
subtypes can only be as complete as the studied samples are representative.
Methods: The Autism Inpatient Collection (AIC) is a multi-site study enrolling children and adolescents with ASD
aged 4–20 years admitted to six specialized inpatient psychiatry units. Enrollment began March, 2014, and
continues at a rate of over 400 children annually. Measures characterizing adaptive and cognitive functioning,
communication, externalizing behaviors, emotion regulation, psychiatric co-morbidity, self-injurious behavior, parent
stress, and parent self-efficacy are collected. ASD diagnosis is confirmed by the Autism Diagnostic Observation
Schedule – 2 (ADOS-2) and extensive inpatient observation. Biological samples from probands and their biological
parents are banked and processed for DNA extraction and creation of lymphoblastoid cell lines.
Results: Sixty-one percent of eligible subjects were enrolled. The first 147 subjects were an average of 12.6 years
old (SD 3.42, range 4–20); 26.5 % female; 74.8 % Caucasian, and 81.6 % non-Hispanic/non-Latino. Mean non-verbal
intelligence quotient IQ = 70.9 (SD 29.16, range 30–137) and mean adaptive behavior composite score = 55.6
(SD 12.9, range 27–96). A majority of subjects (52.4 %) were non- or minimally verbal. The average Aberrant
Behavior Checklist - Irritability Subscale score was 28.6, well above the typical threshold for clinically concerning
externalizing behaviors, and 26.5 % of the sample engaged in SIB. Females had more frequent and severe SIB
than males.
Conclusions: Preliminary data indicate that the AIC has a rich representation of the portion of the autism spectrum
that is understudied and underrepresented in extant data collections. More than half of the sample is non- or
minimally verbal, over 40 % have intellectual disability, and over one quarter exhibit SIB. The AIC is a substantial
new resource for study of the full autism spectrum, which will augment existing data on higher-functioning cohorts
and facilitate the identification of genetic subtypes and novel treatment targets. The AIC investigators welcome
collaborations with other investigators, and access to the AIC phenotypic data and biosamples may be requested
through the Simons Foundation (www.sfari.org).
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Autism spectrum disorder (ASD) is characterized by a
wide range of deficits in social communication and
restricted, repetitive behaviors and interests [1]. It has
recently been noted that those most severely affected by
ASD, including those with intellectual disability, expres-
sive language impairment (non- or minimally verbal),
low adaptive functioning, and/or externalizing behaviors,
have been understudied [2]. Severely affected individuals
with ASD are underrepresented in extant large collec-
tions of phenotypic and genomic data available to inves-
tigators, which may limit the field’s understanding of
ASD etiology, and certainly has a negative impact on the
ability to effectively treat these patients. These know-
ledge gaps are also of great clinical concern, as commu-
nicative and cognitive abilities are the best predictors of
long-term outcomes in children with ASD [3, 4]. Devel-
oping a research platform that can systematically assess
large numbers of severely affected individuals may accel-
erate the pace of ASD etiological research and provide
unique opportunities to identify ASD subtypes and test
targeted treatments.
Barriers to the study of children who are more severely
affected by ASD include challenges in recruitment in
outpatient settings and the relative lack of measures that
have been validated for use with non-verbal or intellec-
tually disabled individuals with ASD. In addition, it may
be easier for investigators to perform some research pro-
cedures, such as phlebotomy, neuroimaging, and physio-
logic measurements, with a more able sample. When
faced with a population difficult to study in the out-
patient setting, the National Institute of Mental Health
has previously employed inpatient research units to per-
form intensive characterization of other complex disor-
ders, such as childhood onset schizophrenia [5].
To address the paucity of research on this segment of
the ASD population, the authors formed the Autism and
Developmental Disorders Inpatient Research Collaborative
(ADDIRC), a network of six specialized hospital psychiatry
units in the United States, and engaged with several aut-
ism philanthropic foundations to explore opportunities to
leverage our unique resources and access to these chil-
dren. Prior survey data indicated a high volume of patients
in specialized inpatient units likely had ASD with intellec-
tual disability, expressive language impairment, and/or
externalizing problem behaviors [6]. When considering
how to systematically assess and leverage this population,
we noted the success of the Simons Simplex Collection
(SSC), which produced a searchable database of pheno-
typic data and corresponding biological samples from
more than 2700 autism families, contributed to large gene
sequencing efforts and spawned over 100 publications.
The SSC was conducted with outpatients who were rela-
tively high functioning and predominantly male (meannon-verbal intelligence quotient (IQ) = 86.5, Vineland
Adaptive Behavior Scale standard score = 74.0, and 85 %
male) [7]. Capitalizing on the unique population and
resources of the inpatient setting, and informed by the
experience of the Simons Foundation in creating the SSC,
we initiated the Autism Inpatient Collection (AIC) to pro-
vide a resource for study of the full autism spectrum. Our
long-term goals include contributing to efforts to assemble
cohorts with rare mutations, copy number variants, and
other chromosomal anomalies that are large enough for
meaningful description and analysis, in order to accelerate
the identification of autism subtypes and targeted
treatments.
The goals of this preliminary study were to test the
feasibility of using the specialized inpatient setting to
perform systematic autism research and to begin to
characterize the population of children and adolescents
with ASD who are admitted for inpatient psychiatric
care. We expected that the AIC would contain a
relatively high proportion of individuals with autism and
intellectual disability, female gender, low adaptive func-
tioning, and/or minimal to non-verbal language status,
and that the inpatient setting might facilitate high rates
of enrollment. Here we describe the preliminary charac-
teristics of the first 147 subjects in the AIC cohort and
methods used to obtain the data.
Methods
The AIC study is being conducted in six academically
affiliated specialized child psychiatry hospital units:
Bradley Hospital (Brown University; RI), Cincinnati
Children’s Hospital (University of Cincinnati; OH),
Children’s Hospital Colorado (University of Colorado, CO),
Sheppard Pratt Health Systems (University of Maryland,
MD), Western Psychiatric Institute and Clinics (University
of Pittsburgh, PA), and Spring Harbor Hospital/Maine
Medical Center Research Institute (Tufts University; ME),
which also serves as the AIC coordinating site with data
and analytic cores. The units specialize in the assessment
and treatment of children with ASD and other develop-
mental disorders. The programs utilize a multi-disciplinary
bio-behavioral approach that substantially differs from
standard inpatient child psychiatric care [8]. Children are
typically admitted due to externalizing problem behaviors
(aggression, self-injury, or tantrums) [9, 10], and admis-
sions are funded by public and private health insurance.
The study protocol and standard operating procedures
were developed through a series of teleconferences with
participating sites and an in-person study launch meet-
ing. Research assistants underwent a 2-day training at
the coordinating site on informed consent administra-
tion, data collection, and data security procedures and
receive continued support via weekly calls with the pro-
ject manager to review study procedures, compliance,
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the coordinating site after initiation of data collection to
review protocol fidelity, regulatory compliance, and
documentation of informed consent. A scientific advis-
ory group and coordinating site advisory group provide
guidance on scientific and administrative issues, and an
interactive relationship with the funding organizations
leverages their prior experience and expertise in assem-
bling large collections.
Patient recruitment
Children admitted to the hospital units were screened
for study eligibility using the Social Communication
Questionnaire [11]. Children with a score of ≥12 on the
SCQ, or who scored less than 12 but were referred by
the inpatient team due to high suspicion of ASD, were
eligible for enrollment. Subjects who met inclusion cri-
teria and whose legal guardian provided informed con-
sent within 5 days of admission were offered enrollment
in the study. Inclusion criteria were as follows: age 4 to
20 years, not having “prisoner” status (on probation or
house arrest), and having at least one guardian who
spoke and read English proficiently and who knew the
child at 4–5 years of age.
The informed consent form requested permission to
re-contact families for future studies, and participants
were asked to enroll in the Autism Inpatient Community
at the Interactive Autism Network (AIC@IAN), an on-
line community that will facilitate dissemination of study
results and re-contacting of the study cohort. Permis-
sions for collection, storage, and future access to bio-
samples (blood, saliva, plasma) were also requested,
utilizing the NIH-recommended language for genetic
studies of subject biomaterials. Consent was also ob-
tained for transfer of de-identified data to a searchable
online data portal (SFARI Base) and the National
Database for Autism Research (NDAR). To protect the
privacy of subjects, and to facilitate the linking of pheno-
typic and biological data, a global unique identifier
(GUID) [12] was assigned to each subject and family
member. The study protocol was approved by the Insti-
tutional Review Board at each of the six investigating
sites: the Cincinnati Children’s Hospital Medical Center
Human Research Program, the Lifespan – Rhode Island
Hospital Research Protection Office, the Maine Medical
Center Office of Research Compliance, the Sheppard
Pratt Institutional Review Board, the University of
Pittsburgh Research Conduct and Compliance Office, and
the University of Colorado Denver Office of Regulatory
Compliance.
Evaluation of probands and families
The diagnosis of ASD was made by a research-reliable
Autism Diagnostic Observation Scale – 2 (ADOS-2) [13]examiner using DSM 5 criteria, including ADOS-2
results in addition to a review of study measures and
inpatient observation. Diagnosis of ASD required meet-
ing the empirically derived cutoffs for autism or autism
spectrum disorder on the ADOS-2. Clinical assessment,
using all available data, indicating that a child did not
have ASD could override a positive ADOS-2. Develop-
mentally delayed children who screened positive with an
SCQ score of ≥12 and were enrolled in the study, but
who were found to not have ASD, will ultimately serve
as a small non-ASD comparison population. ADOS-2
examiners, who were master’s or doctoral level clinicians
with extensive experience evaluating children with ASD,
underwent a 2-day initial research reliability training ses-
sion with a certified ADOS-2 trainer (RLG), and then
achieved at least 80 % inter-rater reliability with the
trainer on two consecutive ADOS-2 administrations of
each module set (Modules 1 and 2; Modules 3 and 4)
per current research reliability standards established by
the test authors [13]. To minimize administration and
coding drift, monthly calls were held with the ADOS-2
examiners and trainer, and a 2-day recalibration meeting
was held 6 months after study initiation.
An assessment battery was developed with a focus on
domains most relevant to this population and measures
appropriate for use in those with intellectual disability or
non-verbal status (see Table 1). A primary caregiver pro-
vided demographic information, family composition,
proband and family medical and psychiatric history, and
the proband medication profile. The caregiver was then ad-
ministered the Aberrant Behavior Checklist – Community
(ABC-C) [14], Repetitive Behavior Scale – Revised – Self-
Injury Subscale [15], Child and Adolescent Symptom
Inventory 5 [16], Vineland-2 parent report form [17],
Parent Stress Index – 4 – Short Form [18], Difficult
Behavior Self-Efficacy Scale (DBSES) [19], and a newly
developed measure – the Emotion Dysregulation Index
(EDI). The EDI is a treatment-sensitive outcome measure
of emotional distress and problems with emotion re-
gulation designed to be valid for the full range of cognitive
and communication abilities in children with autism
(R01HD079512) [20]. The EDI was repeated at discharge,
and the ABC-C – Irritability and Hyperactivity Subscales,
PSI-4-SF, DBSES, and medication profile were repeated at
discharge and by telephone at 2-month follow-up. Self-
injurious behavior (SIB) was also evaluated by administra-
tion of the Functional Assessment Screening Tool [21] to
the caregiver and an inpatient staff member, and a final de-
termination of the presence of clinically significant SIB and
its function was made by the unit behavioral specialist
(psychologist or board certified behavior analyst (BCBA)),
based on all available information. Axis 1 co-morbid
psychiatric disorders and Axis 3 medical conditions were
recorded at discharge.
Table 1 AIC study measures
Measure Domain/construct Format
ADOS-2 Diagnostic confirmation; repetitive behaviors and
social communication
Structured assessment
Social Communication Questionnaire (SCQ) Diagnostic screen; repetitive behaviors and
social communication
Parent report
Aberrant Behavior Checklist (ABC) Challenging behaviors Parent report
Repetitive Behavior Scale Revised (RBS-R) –
Self-Injury Subscale
Self-injurious behavior Parent report
Functional Assessment Screening Tool (FAST) Behavioral function for self-injurious behavior Parent and observer report
Vineland-2 Adaptive functioning and communication Parent report
Difficult Behavior Self-Efficacy Scale (DBSES) Self-efficacy Parent report
Leiter 3 Cognitive ability Structured assessment
Child and Adolescent Symptom Inventory (CASI-5) Psychiatric symptoms and disorder cutoffs Parent report
Parent Stress Index Parenting stress Parent report
Emotion Dysregulation Inventory (EDI) Emotional distress and problems with
emotion regulation
Parent report
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Phenotypic data were collected on paper forms and en-
tered at each site into a web-based, HIPPA-compliant
central database through the Research Electronic Data
Capture (REDCap) system. The REDCap database was
built with over 100 logic checks to detect and reduce
data entry errors and is monitored by the study data co-
ordinator. Whole blood was collected from the proband
and biological parents in one EDTA vacutainer tube and
two sodium citrate tubes. If blood could not be obtained,
a saliva sample was collected using an Oragene-DNA
(OGR-500) 2-ml saliva collection tube. Samples were
shipped to the Rutgers University Cell and DNA Reposi-
tory (RUCDR), where DNA was extracted from blood or
saliva, plasma was stored, and lymphoblastoid cell lines
were created. Phenotypic and biological data were linked
by a GUID. The phenotypic data will be made available
by the Simons Foundation through an interactive plat-
form, SFARI Base, and access to both the phenotypic
data and biological samples can be requested from the
Simons Foundation by qualified investigators. After pri-
mary analyses are completed, phenotypic data will also
be sent to the National Database for Autism Research
(NDAR). In addition, we are collaborating with the
Autism Sequencing Consortium (ASC), and whole
exome sequencing data on these samples will be released
to the database of Genotypes and Phenotypes (dbGaP)
by the ASC as they become available.
Analysis
Descriptive statistics were computed using means and
standard deviations for continuous variables (Medians
(Md) for non-parametric data), and frequencies and pro-
portions for categorical variables. To examine potential
gender differences, we conducted Independent SamplesT tests (Mann-Whitney U tests for non-parametric data)
or chi-square tests for continuous and categorical
data, respectively. Statistical significance is indicated
by p values ≤0.05.
Intellectual disability was defined as a non-verbal IQ
of ≤70, low adaptive functioning was defined as a
Vineland Adaptive Behavior Scale – 2 (VABS-2) score ≤70,
non-verbal and minimally verbal status was defined as use
of an ADOS-2 Module 1 or 2, and the presence of clinic-
ally significant externalizing problem behaviors was
defined as an Aberrant Behavior Checklist – Irritability
Subscale score of ≥16 [22]. Self-injurious behavior was de-
fined as the presence of at least daily attempts at self-
injury, as determined by the unit psychologist or board
certified behavior analyst.
Results
Of the first 470 children screened for study eligibility,
351 met inclusion criteria and 213 (61 %) were enrolled
(see Fig. 1). One hundred forty-seven enrolled subjects
(69 %) were confirmed to have a diagnosis of ASD at
the time of this preliminary analysis. The sample was
26.5 % female, had a mean age of 12.6 years, and was
74.8 % Caucasian and 81.6 % non-Hispanic/non-Latino
(see Table 1).
As expected, a sizable proportion of the study sample
had intellectual disability (ID) (42.6 %), expressive
language impairment (52.4 % non- or minimally verbal),
low adaptive functioning (71.9 %), and/or externalizing
problem behaviors (85.4 % ≥16 on ABC – Irritability
Subscale). Mean non-verbal IQ for the sample was 70.86
(SD 29.16, range 30–137) as measured on the Leiter 3,
and the mean Adaptive Behavior Composite on the
VABS-2 was in the extremely low range (M 55.57, SD
12.88, range 27–96). The average VABS-2 Expressive
Fig. 1 Autism inpatient collection preliminary sample
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(SD 3.92, range 1–17), which is almost 3 standard devia-
tions below the population mean of 15 [17]. Fifty-two
percent of the sample was non-verbal or minimally verbal.
Self-injurious behavior was present in 26.5 % of the
sample, and the mean score on the Aberrant Behavior
Checklist – Irritability Subscale was 28.6 (SD 8.6, range
8–45), well above the typical entry criteria score of 16
for treatment studies targeting externalizing problem
behaviors.
Female subjects had a lower mean non-verbal IQ and a
notably higher rate of self-injurious behavior (SIB) (33 %),
compared to males (24 %) (Fig. 2). The frequency and
severity of SIB, as measured by the RBS-R – Self-Injury
Subscale score, was significantly higher for females in boththe total sample (females Md = 10.0, n = 35, males
Md = 7.0, n = 93, Mann-Whitney U = 1113.50, z = −2.75,
p = .006, r = 0.24) and in those with clinically signifi-
cant SIB (females Md = 15.0, n = 13, males Md = 9.0,
n = 26, Mann-Whitney U = 77.50, z = −2.73, p = .006,
r = 0.44) (Table 2).
Discussion
Preliminary results from the first 147 subjects with ASD
enrolled in the Autism Inpatient Collection (AIC) sup-
port the feasibility of utilizing the specialized inpatient
psychiatric unit setting to study complex disorders with
variable presentations, and the opportunity to capture
the full range of ASD severity. Enrollment of 61 % of
eligible subjects within 5 days of admission, in the
Fig. 2 Non-verbal IQ distribution
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a blood draw, suggests that the inpatient setting is an
efficient means of recruiting and assessing research par-
ticipants with ASD, including those who may be difficult
to reach or assess in the outpatient setting. The AIC
cohort is notable in its average severity of impairment
across a number of phenotypic domains including cogni-
tive ability, adaptive functioning, expressive language,
and externalizing problem behaviors. Simultaneously,
the cohort captures the full range of ASD severity, as
reflected by scores that range from severe impairment to
superior functioning.
Over one fourth (26.5 %) of the sample is female,
which is higher than the rate of 22.5 % reported by the
Centers for Disease Control [23] and higher than other
comparable large-scale ASD collections, such as the SSC
which is 15.4 % female [7]. The higher rate of females
may be attributed to the fact that our sample is weighted
toward the more severely affected, as the prevalence of
ASD in females is greater among those with severe
cognitive impairment [24]. The largest study of gender
differences in ASD to date found that females had
significantly higher rates of both general externalizing
problems and SIB than males [25]. In the AIC sample,
approximately one third of females were observed to
engage in daily SIB and they had significantly greater
frequency and severity of SIB than males. Given therelatively high proportion of females and prevalence of
SIB in our sample, the AIC data offer an opportunity
to better describe and understand the female autism
phenotype.
The frequency of co-occurrence of intellectual disabil-
ity (ID) in individuals with ASD has varied substantially
across studies and over time. Most current epidemio-
logic studies cite a prevalence of ID of 20–40 % [23, 26].
Taking a conservative approach, we utilized the Leiter 3
non-verbal IQ test in order to provide the greatest
chance for even very impaired subjects to provide a reli-
able estimate of their cognitive ability. Despite this,
nearly half the sample scored in the ID range, and al-
most three quarters had extremely low adaptive func-
tioning. These numbers may still underestimate the
severity of intellectual disability in the cohort, as 11
subjects (7.5 %) were unable to perform the Leiter
tasks, suggesting they may have a mental age of less
than 3 years, which is below the floor for the Leiter
test. Greater degrees of intellectual disability in ASD
have been associated with decreased expressive lan-
guage, increased rates of self-injury, and specific gen-
etic anomalies. As the cohort grows, interrogating the
genomes of AIC participants may shed light on the
specific and synergistic contributions of polymorphisms
and mutations associated with ASD and intellectual
disability.
Table 2 Sample characteristics
Overall sample Males Females
(n = 147) (n = 108) (n = 39)
Mean (SD)/N (%) Range Mean (SD)/N (%) Range Mean (SD)/N (%) Range
Age (years) 12.58 (3.42) 4–20 12.55 (3.55) 4–20 12.67 (3.07) 6–18
Ethnicity (non-Hispanic/Latino) 120 (81.6 %) 86 (79.6 %) 34 (87.2 %)
Race (White) 110 (74.8 %) 83 (76.9 %) 27 (69.2 %)
Non-verbal IQ (n = 117) 70.86 (29.16) 30–137 73.01 (29.84) 30–137 64.63 (25.56) 31–113
Expressive Communication Subscale (Vineland-2) 6.55 (3.92) 1–17 6.65 (4.05) 1–17 6.26 (3.53) 1–17
Adaptive Behavior Composite (Vineland-2) (n = 128) 55.57 (12.88) 27–96 55.33 (12.79) 27–96 56.27 (13.36) 29–78
ADOS-2 Module administered
1 62 (42.2 %) 46 (42.6 %) 16 (41 %)
2 15 (10.2 %) 9 (8.3 %) 6 (15.4 %)
3 57 (38.8 %) 43 (39.8 %) 14 (35.9 %)
4 13 (8.8 %) 10 (9.3 %) 3 (7.7 %)
ADOS-2 scores: Modules 1, 2, and 3 only (n = 134)
Comparison score 7.47 (1.57) 4–10 7.52 (1.55) 4–10 7.36 (1.64) 4–10
Social affect 13.44 (4.26) 2–20 13.4 (4.23) 2–20 13.56 (4.16) 5–20
Restricted/repetitive behaviors 3.44 (2.12) 0–8 3.50 (2.11) 0–8 3.28 (2.16) 0–7
ADOS-2 scores: Module 4 only (n = 13)
Social and communication 12.31 (3.40) 8–19 12.0 (2.87) 8–16 13.33 (5.51) 8–19
Stereotyped behaviors and restricted interests 2.92 (3.23) 0–13 3.20 (3.55) 1–13 2.0 (2.0) 0–4
Aberrant Behavior Checklist (ABC) Subscales
Irritability 28.58 (8.6) 8–45 27.72 (8.5) 8–45 31.15 (8.2) 10–42
Lethargy 15.98 (8.5) 1–44 15.99 (8.6) 1–44 15.94 (8.3) 1–39
Stereotypy 8.98 (5.7) 0–20 8.62 (5.6) 0–20 10.06 (5.9) 2–20
Hyperactivity 30.58 (10.2) 1–47 30.73 (10.4) 1–47 30.15 (9.7) 11–45
Inappropriate speech 5.61 (3.8) 0–12 5.61 (3.8) 0–12 7.03 (3.6) 0–12
Self-injurious behavior (SIB) present 39 (26.5 %) 26 (24.1 %) 13 (33.3 %)
Repetitive Behavior Scale – Revised (RBS-R) –
Self-Injury Subscale total score for subjects with
SIB present (n = 39)
n = 39 n = 26 n = 13
Md = 11.0 Md = 9.0a Md = 15.0a
Md median
aSignificant difference between male and female RBS-R scores, Mann-Whitney U = 1113.50, z = −2.75, p = 0.006
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tigate individuals with significant expressive language
impairment, an area identified as under-researched by
the Inter-Agency Autism Coordinating Committee of
the NIH [2]. Over half of the AIC sample is non-verbal
or minimally verbal. This most likely represents a stable
language status, rather than a pre-verbal condition, as
the mean age of the AIC is 12.6 years, almost all subjects
are older than 5 years, and the likelihood of a substantial
change in verbal status (from non- or minimally verbal
to verbally fluent) decreases dramatically after age 6
[27]. Communication is one of the two core deficits in
autism, but research and treatment of individuals with
ASD and serious expressive language impairment has
been slowed by a lack of gold standard research methodsfor characterizing verbal status or communication abil-
ity, great heterogeneity in the use of clinical measures,
and the absence of a consistent definition of non-verbal
status [28]. Very little is known, in particular, about
school-age children with ASD who are non-verbal or
minimally verbal. As over 50 % of the AIC sample is in
this category, this may represent a research opportunity
for this often neglected segment of children with ASD.
Externalizing problem behaviors are often the primary
reasons for children with ASD to present for treatment
in all settings, not just to inpatient units [29], and are
highly predictive of caregiver stress [30]. The AIC
sample includes a high proportion of children with these
behaviors, a group that is often excluded or unable to
participate in outpatient studies, particularly large-scale
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nalizing problem behaviors in ASD are typically mea-
sured by the Aberrant Behavior Checklist – Irritability
Subscale, which captures physical aggression, self-injurious
behavior (SIB), and tantrums. In the AIC sample, the mean
ABC-I score was 28.6, which is similar to the pre-
treatment score of ASD samples recruited for antipsychotic
medication clinical trials [22, 31], indicating that the
average AIC subject has serious behavioral disturbance.
Moving beyond the parent-reported ABC-I, the size of the
AIC sample and range of measures collected offers the
opportunity to examine factors that may underlie these
behaviors, particularly through the use of latent-class
multi-level modeling.
Self-injurious behavior, in particular, is prevalent in the
sample and is an under-recognized source of impairment
in ASD. SIB has been shown to occur at twice the rate
of physical aggression in a community ASD sample [32].
Despite its prevalence, the conceptualization and meas-
urement of SIB varies by reporter and environment [33].
SIB is also the subject of few large studies, primarily re-
ceiving attention in single-case designs in the applied be-
havioral analysis literature. Not surprisingly, evidence for
SIB treatment options other than individualized behav-
ioral analysis is minimal, and includes no proven
pharmacologic treatments. The size of the AIC sample
exhibiting SIB as well as the behavioral expertise and
opportunity for 24-h observation on the inpatient units
offer the possibility for more refined measurement and
novel mechanistic, physiologic, and genetic investiga-
tions of SIB. For example, the combined contributions
of arousal, cognitive control, and emotional dysregula-
tion have been proposed as a trans-diagnostic paradigm
for understanding negative externalizing behaviors in
autism [34], and may be ideal to investigate in the
laboratory-like setting of the hospital unit.
Looking ahead, we continue to expand the size of the
AIC cohort in order to provide a sample size adequate
for phenotype–genotype explorations for autism sub-
types. We also seek to capitalize on the availability of
large numbers of individuals with intellectual disability,
expressive language impairment, female gender, and SIB
in order to better understand the challenges, needs, and
treatment options of these subgroups. Efforts have
already begun to include the AIC biosamples in current
large genomic sequencing efforts, such as the Autism
Sequencing Consortium (ASC) [35]. This collaboration
is anticipated to both facilitate access to the AIC
genomic data and to enhance the value of the larger
ASC effort by including more of those who are severely
affected.
The investigators of the AIC welcome collaborations
with other interested investigators. Access to the AIC
phenotypic and genetic data and biosamples can berequested through the Simons Foundation. The data will
be made available through an interactive platform,
SFARI Base, and the phenotypic data will also be sent to
the National Database for Autism Research (NDAR).
Whole exome sequencing data on these samples will be
released to dbGaP by the Autism Sequencing Consortium
as they become available.Limitations
Results presented here are preliminary, based upon the
first 147 subjects in the AIC; characteristics of the full
AIC sample may vary somewhat. Although the control
group is not yet large enough for meaningful compari-
son, we will, in future reports, include a statistical com-
parison with a comparison group of individuals with
non-ASD developmental delay that are enrolled but fail
to meet criteria for ASD. Finally, although the strength
of the AIC is the inclusion of individuals typically under-
represented in outpatient studies, results may be limited
in their generalizability to the broader autism population
as the collection is composed of children who have been
hospitalized due to externalizing problem behaviors.Conclusions
Preliminary results indicate that the Autism Inpatient
Collection may be a valuable cohort for ASD research.
The sample is older and has a higher proportion of
females, lower intellectual and adaptive functioning,
greater expressive language impairment, and higher rates
of self-injury and other externalizing problem behaviors
than most other large collections currently available to
investigators. The availability of these data, and corre-
sponding biosamples and genomic data, through the
Simons Foundation and NDAR, may accelerate the
identification of genetically distinct autism subtypes and
provide opportunities for re-contacting of cohorts to iden-
tify unmet medical needs and potential treatment targets.Abbreviations
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